PCN101 A Cost-Effectiveness Analysis for Second-Line Treatment of Relapsed/Refractory (RR) Multiple Myeloma (MM) in the United Kingdom
Nov 1, 2011, 00:00 AM
10.1016/j.jval.2011.08.1202
https://www.valueinhealthjournal.com/article/S1098-3015(11)02764-1/fulltext
Section Title :
Cancer
Section Order :
1157
First Page :
A452
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)02764-1&doi=10.1016/j.jval.2011.08.1202